Journals / E Journal of Cardiovascular Medicine / 2019 / Cilt: 7 - Sayı: 1

Tranexamic Acid, a Low-cost and Practical Hemostatic Agent Against Diffuse Microvascular Bleeding Due to Coagulopathy in Heart Surgery

Pages
16–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We think that tranexamic acid, which is used as a low-cost and effective pharmacological agent in heart surgery, will significantly reduce post-operative bleeding and the need for blood transfusion in patients undergoing heart surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Bleeding after open heart surgery is an important cause of morbidity and mortality.
📊
Key Findings & Data:Materials and Methods: A total of 24 patients were enrolled in the study at the Hisar Intercontinental Hospital between March 2017-December 2017. 12 patients were administered tranexamic acid 10% 500 mg I.V. before starting sternal incision for open heart surgery. 10% 500 mg I.V. tranexamic acid dose was repeated during separation from the heart-lung machine at the end of the operation.
💡
Conclusion & Impact:Conclusion: We think that tranexamic acid, which is used as a low-cost and effective pharmacological agent in heart surgery, will significantly reduce post-operative bleeding and the need for blood transfusion in patients undergoing heart surgery.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Bleeding after open heart surgery is an important cause of morbidity and mortality. It may not always be related to surgical bleeding. Bleeding due to coagulopathy, called diffuse microvascular bleeding, is more commonly seen in the post-operative period. The objective of this study is to assess the effect of administering transamine, which we consider a low-cost and effective hemostatic agent, during open heart surgery on postoperative bleeding amount, blood product use, length of stay in intensive care, and duration of hospitalization. Materials and Methods: A total of 24 patients were enrolled in the study at the Hisar Intercontinental Hospital between March 2017-December 2017. 12 patients were administered tranexamic acid 10% 500 mg I.V. before starting sternal incision for open heart surgery. 10% 500 mg I.V. tranexamic acid dose was repeated during separation from the heart-lung machine at the end of the operation. The other 12 patients were followed-up as a control group. Patients were followed-up for drainage in the post-operative period. The patients were monitored for re-operation due to bleeding and significant side effects. Bleeding amounts and re-operation rates were compared. Results: When the results from the two groups were evaluated, revision rates, amounts of used blood and blood products, total drainage amount were less, and stay in intensive care and discharge time were shorter in the group given tranexamic acid. Conclusion: We think that tranexamic acid, which is used as a low-cost and effective pharmacological agent in heart surgery, will significantly reduce post-operative bleeding and the need for blood transfusion in patients undergoing heart surgery.

🔖

Cite This Article

KARA, K. A., ÖNTAŞ, H. (2019). Tranexamic Acid, a Low-cost and Practical Hemostatic Agent Against Diffuse Microvascular Bleeding Due to Coagulopathy in Heart Surgery. E Journal of Cardiovascular Medicine, Cilt: 7 - Sayı: 1, 16–21. https://ajindex.com/articles/154314

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Yeh T Jr, Shelton L, Yeh TJ. Blood loss and bank blood requirement in coronary bypass surgery. Ann Thorac Surg 1978;26:11-6.
  2. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993;106:11-8.
  3. Casati V, Guzzon D, Oppizzi M, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000;120:520-7.
  4. Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg 1998;87:258-65. Zuck TF. Transfusion-transmitted AIDS reassessed. N Engl J Med 1988;318:511-2.
  5. Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol 1986;23:223-9.
  6. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alphagranule release. Blood 1980;56:824-34.
  7. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;107:271-9.
  8. Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-51.
  9. Tatar H, Çiçek S, Demirkiliç U, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993;55:659-61.
  10. De Bonis M, Cavaliere F, Alessandrini F, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 2000;119:575-80.
  11. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Páramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921- 7. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospec